Disclaimer for the US market

The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.

Neither the Company nor its representatives is providing any medical advice, and none should be inferred, from any ideas, suggestions, testimonials or other information set forth on this website or in other Company materials or provided over the phone, in the mail, in product packaging, or in email correspondence. This website may contain links to third-party websites. The Company provides these links as a convenience only and does not endorse any of these sites. The Company is not responsible for the content of, and does not make any representations regarding the materials on, such linked third-party websites. If you decide to access or rely on information at linked third-party website, you do so at our own risk. Our terms and conditions, including disclaimers, are more fully set forth in our Terms of Use, Privacy Policy and Terms of Online Sales.

Close

Member of the Medical Alliance Team of Resuscitec GmbH receives German Resuscitation Council Young Investigator Award

Sam Brixius, PhD student at the Clinic for Cardiovascular Surgery at the Freiburg University Hospital and member of the Medical Alliance Team of Resuscitec GmbH, has been awarded with the German Resuscitation Council Young Investigator Award, which is offered on a rotational basis by the German Resuscitation Council. The prize recognizes the commitment of young scientists in resuscitation research and is endowed with a prize money of EUR 1,500 per winner. The official award ceremony will take place at the GRC Resuscitation Dialogue 2022.

As part of his dissertation, Brixius investigated the extent to which the controlled, automated whole-body reperfusion conceptualized in Freiburg, known as CARL, offers advantages over extracorporeal cardiopulmonary resuscitation according to established standards.

Professor Dr. Andreas Bohn reported for the expert jury: “In his model, Brixius was able to show that extracorporeal reperfusion after a 5-minute cardiac arrest and thirty minutes of resuscitation in accordance with guidelines thereafter leads to severe hypotensive phases and massive hyperoxygenation with simultaneous hypercapnia. The early detection and controlled modifying of several reperfusion parameters in the context of CARL Therapy was shown to be beneficial with regard to the above-mentioned points. Sam Brixius intends to pursue further unanswered questions in the future. The winner of the GRC Young Investigator Award could prevail within a very strong field of applicants. The jury was very pleased about the numerous prize applications, thanked all applicants and congratulated Sam Brixius very warmly!”

The German Resuscitation Council (GRC) was founded in December 2007 and counts now over 1,600 members, 18 member organizations, 37 sponsoring members and numerous business partners. The goal of the GRC is to support and harmonize interdisciplinary cooperation between organizations and individuals involved in the various aspects of resuscitation and to promote lay resuscitation and student education in this regard.

< Back